Literature DB >> 8226319

Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic.

K Takesako1, H Kuroda, T Inoue, F Haruna, Y Yoshikawa, I Kato, K Uchida, T Hiratani, H Yamaguchi.   

Abstract

Aureobasidin A (AbA) is a novel cyclic depsipeptide antifungal antibiotic. The antifungal activity of AbA was studied in vitro and in vivo in comparison with clinically effective antifungal agents, amphotericin B and fluconazole. AbA was highly active in vitro against many pathogenic fungi, including Candida albicans, Cryptococcus neoformans, Blastomyces dermatitidis and Histoplasma capsulatum. The activity was superior to amphotericin B in most cases. AbA exhibited fungicidal action toward growing cultures of C. albicans. It was highly tolerated by mice and showed good efficacy in the treatment of murine systemic candidiasis when given orally or subcutaneously. AbA's fungicidal action in mice with candidiasis was more effective than fluconazole and amphotericin B.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8226319     DOI: 10.7164/antibiotics.46.1414

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  37 in total

Review 1.  Antifungal peptides: novel therapeutic compounds against emerging pathogens.

Authors:  A J De Lucca; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Inhibition of inositol phosphorylceramide synthase by aureobasidin A in Candida and Aspergillus species.

Authors:  W Zhong; M W Jeffries; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 3.  The Future of Antifungal Drug Therapy: Novel Compounds and Targets.

Authors:  Caroline Mota Fernandes; Deveney Dasilva; Krupanandan Haranahalli; J Brian McCarthy; John Mallamo; Iwao Ojima; Maurizio Del Poeta
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

4.  Saccharomyces cerevisiae Is Dependent on Vesicular Traffic between the Golgi Apparatus and the Vacuole When Inositolphosphorylceramide Synthase Aur1 Is Inactivated.

Authors:  Natalia S Voynova; Carole Roubaty; Hector M Vazquez; Shamroop K Mallela; Christer S Ejsing; Andreas Conzelmann
Journal:  Eukaryot Cell       Date:  2015-10-02

5.  Generation of Broad-Spectrum Antifungal Drug Candidates from the Natural Product Compound Aureobasidin A.

Authors:  Peter G M Wuts; Lloyd J Simons; Brian P Metzger; Rachel C Sterling; Jerry L Slightom; Ake P Elhammer
Journal:  ACS Med Chem Lett       Date:  2015-04-23       Impact factor: 4.345

6.  Fungicidal action of aureobasidin A, a cyclic depsipeptide antifungal antibiotic, against Saccharomyces cerevisiae.

Authors:  M Endo; K Takesako; I Kato; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  A computational approach to the inference of sphingolipid pathways from the genome of Aspergillus fumigatus.

Authors:  Jin Hwan Do; Tae-Kyu Park; Dong-Kug Choi
Journal:  Curr Genet       Date:  2005-09-14       Impact factor: 3.886

8.  Effect of anti-glycosphingolipid monoclonal antibodies in pathogenic fungal growth and differentiation. Characterization of monoclonal antibody MEST-3 directed to Manpalpha1-->3Manpalpha1-->2IPC.

Authors:  Marcos S Toledo; Loriane Tagliari; Erika Suzuki; Claudinei M Silva; Anita H Straus; Helio K Takahashi
Journal:  BMC Microbiol       Date:  2010-02-15       Impact factor: 3.605

9.  Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.

Authors:  Paul A Aeed; Casey L Young; Marek M Nagiec; Ake P Elhammer
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

Review 10.  Fungal sphingolipids: role in the regulation of virulence and potential as targets for future antifungal therapies.

Authors:  Caroline Mota Fernandes; Maurizio Del Poeta
Journal:  Expert Rev Anti Infect Ther       Date:  2020-07-16       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.